Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$0.67 USD
+0.01 (0.75%)
Updated Apr 23, 2024 04:00 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Chemomab Therapeutics Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 20 | 40 | 61 | 5 | 18 |
Receivables | 1 | 0 | 2 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 2 | 0 | 1 | 0 |
Total Current Assets | 21 | 42 | 63 | 6 | 18 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 0 | 0 |
Total Assets | 22 | 43 | 64 | 6 | 20 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 1 | 2 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 1 | 0 | 3 |
Total Current Liabilities | 5 | 7 | 3 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 7 | 3 | 3 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 106 | 101 | 98 | 120 | 119 |
Retained Earnings | -89 | -64 | -36 | -117 | -105 |
Other Equity | 0 | 0 | 0 | 1 | 1 |
Treasury Stock | 0 | 1 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 36 | 61 | 4 | 15 |
Total Liabilities & Shareholder's Equity | 22 | 43 | 64 | 6 | 20 |
Total Common Equity | 17 | 36 | 61 | 4 | 15 |
Shares Outstanding | 11.00 | 11.60 | 11.40 | 2.30 | 0.40 |
Book Value Per Share | 1.55 | 3.12 | 5.39 | 1.56 | 37.28 |
Fiscal Year End for Chemomab Therapeutics Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 20 | 21 | 27 | 33 |
Receivables | NA | 1 | 1 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 1 | 1 |
Total Current Assets | NA | 21 | 22 | 28 | 34 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 22 | 23 | 29 | 35 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 3 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 2 | 2 | 2 |
Total Current Liabilities | NA | 5 | 5 | 7 | 7 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 5 | 5 | 7 | 7 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 106 | 104 | 104 | 102 |
Retained Earnings | NA | -89 | -85 | -81 | -73 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 1 | 1 | 1 |
Total Shareholder's Equity | NA | 17 | 18 | 22 | 28 |
Total Liabilities & Shareholder's Equity | NA | 22 | 23 | 29 | 35 |
Total Common Equity | 0 | 17 | 18 | 22 | 28 |
Shares Outstanding | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 |
Book Value Per Share | 0.00 | 1.55 | 1.64 | 2.00 | 2.54 |